<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="184537">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00691678</url>
  </required_header>
  <id_info>
    <org_study_id>AAAC8748</org_study_id>
    <nct_id>NCT00691678</nct_id>
  </id_info>
  <brief_title>Glucosamine and Chondroitin for Aromatase Inhibitor Induced Joint Symptoms in Women With Breast Cancer</brief_title>
  <official_title>Pase II Study of Glucosamine With Chondroitin on Joint Symptoms Induced By Aromatase Inhibitors in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dawn L. Hershman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators are hoping to learn if glucosamine with chondroitin can help relieve joint
      pain/stiffness associated with aromatase inhibitors
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) criteria (composite endpoint including pain, function, and the patient's global assessment of disease)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucosamine Chondroitin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucosamine Chondroitin</intervention_name>
    <description>Glucosamine [500mg three times daily (TID) x 24 weeks] plus chondroitin (400mg TID x 24 weeks)</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;21 years

          -  Postmenopausal status defined as cessation of menses for &gt;1 year or FSH &gt;20 mIU/mL

          -  History of stage I, II or IIIA hormone receptor-positive breast cancer, without
             metastatic disease

          -  Currently taking a third-generation aromatase inhibitor for at least 3 months

          -  Clinical symptoms of knee and/or hand joint pain and/or stiffness for at least 3
             months prior to study entry

          -  Ongoing musculoskeletal pain/stiffness in hand and/or knee joints (50 or higher on
             the 100 point global assessment VAS) that started or increased since initiating
             aromatase inhibitor therapy, and has been present for at least 3 months.

          -  patients must agree to refrain from use of glucosamine and chondroitin from sources
             outside of this study

          -  If taking bisphosphonates, on a stable dose for at least 3 months and tolerating the
             dose. Patients must agree to refrain from initiating bisphosphonate use during the
             course of the study.

          -  ECOG performance status 0-2.

          -  Hemoglobin A1c &lt;8.

          -  Signed informed consent

        Exclusion Criteria:

          -  se of glucosamine or chondroitin within the past six months

          -  Concurrent medical/arthritic disease that could confound or interfere with evaluation
             of pain or efficacy including:

               -  Inflammatory arthritis (e.g., rheumatoid arthritis, systemic lupus,
                  spondyloarthropathy, psoriatic arthritis, polymyalgia rheumatica)

               -  gout

               -  episodes of acute monarticular arthritis clinically consistent with pseudogout

               -  Paget's disease affecting the study joint

               -  a history of septic arthritis or avascular necrosis or intra-articular fracture
                  of the study joint

               -  Wilson's disease

               -  hemochromatosis

               -  alkaptonuria

               -  primary osteochondromatosis

          -  History of significant collateral ligament, anterior cruciate ligament or meniscal
             injury of the index joint requiring surgery or non-weight bearing (requiring use of
             crutches or cane) for more than 3 weeks (minor ligamentous injury prior to 6 months
             is not an exclusion).

          -  History of bone fracture or surgery of the afflicted knees and/or hands within 6
             months prior to study entry.

          -  AST, ALT &gt; 2x normal.

          -  Serum Creatinine of &gt; 1.8 mg/dl.

          -  Uncontrolled hypertension (Systolic Blood Pressure of &gt; 150 mm Hg or Diastolic Blood
             Pressure of &gt;95 mm Hg).

          -  Uncontrolled diabetes mellitus, defined as Hemoglobin A1c level of &gt; 8%.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawn Hershman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 19, 2013</lastchanged_date>
  <firstreceived_date>June 3, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Dawn L. Hershman</investigator_full_name>
    <investigator_title>Associate Professor of Medicine &amp; Epidemiology</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>aromatase inhibitor</keyword>
  <keyword>supportive care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
